The pituitary tumour epigenome: aberrations and prospects for targeted therapy (Q38004744)

26 August 2017

The pituitary tumour epigenome: aberrations and prospects for targeted therapy (English)

1 reference

26 August 2017

Cuong V Duong

3

0 references

Alan Richardson

object named as

Alan Richardson

2

0 references

author name string

Kiren Yacqub-Usman

1

1 reference

PubMed ID

22525730

26 August 2017

Richard N Clayton

4

1 reference

PubMed ID

22525730

26 August 2017

William E Farrell

5

1 reference

26 August 2017

24 April 2012

1 reference

Nature Reviews Endocrinology

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

8

1 reference

26 August 2017

486-494

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2012.54

26 August 2017

0 references

cites work

Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The epigenomics of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Cancer epigenetics reaches mainstream oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

DNA methyltransferase Dnmt1 associates with histone deacetylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Pituitary tumours: all silent on the epigenetics front

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Pituitary tumours: findings from whole genome analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

CpG-rich islands and the function of DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The distribution of CpG islands in mammalian chromosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Chromatin modifications and their function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Reversal of endogenous dopamine receptor silencing in pituitary cells augments receptor-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Tumor-derived Ikaros 6 acetylates the Bcl-XL promoter to up-regulate a survival signal in pituitary cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Aberrant epigenetic landscape in cancer: how cellular identity goes awry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Towards the human cancer epigenome: a first draft of histone modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetics in human disease and prospects for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Worms gang up on bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Loss of expression of the growth inhibitory gene GADD45gamma, in human pituitary adenomas, is associated with CpG island methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Genome-wide analysis in a murine Dnmt1 knockdown model identifies epigenetically silenced genes in primary human pituitary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Loss of neuronatin expression is associated with promoter hypermethylation in pituitary adenoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Activation of p53 by MEG3 non-coding RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Isolation and characterization of a novel pituitary tumor apoptosis gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Altered expression of fibroblast growth factor receptors in human pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The pathogenesis of pituitary tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

E2F1 activation is responsible for pituitary adenomas induced by HMGA2 gene overexpression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

HMGA2: A pituitary tumour subtype-specific oncogene?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Ikaros is regulated through multiple histone modifications and deoxyribonucleic acid methylation in the pituitary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Methyl CpG binding proteins: coupling chromatin architecture to gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Pituitary tumours: the sst/D2 receptors as molecular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Medical therapy in acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Dopamine as a Prolactin (PRL) Inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Dopamine receptor agonists for treating prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Pharmacologic resistance in prolactinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Abnormal dopamine sensitivity in some human prolactinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Resistance to bromocriptine in prolactinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetic modifications as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Targeting DNA methylation for epigenetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

5-azacytidine treatment reorganizes genomic histone modification patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Chromatin, cancer and drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

p21(Cip1) restrains pituitary tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Decitabine and its role in the treatment of hematopoietic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Preferential response of cancer cells to zebularine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Inhibition of DNA methylation and reactivation of silenced genes by zebularine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetics and cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Cloning and characterization of human estrogen receptor beta promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Modulation of cellular radiation responses by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetic cancer therapy: Proof of concept and remaining challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Chromosomal Instability and Tumors Promoted by DNA Hypomethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

A direct link between core histone acetylation and transcriptionally active chromatin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

The fundamental role of epigenetic events in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Pathogenesis of pituitary tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2012.54

Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition

31 March 2020

1 reference

12 December 2020

Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors

1 reference

12 December 2020

Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer

1 reference

12 December 2020

Structural specificity for biological activity of trichostatin A, a specific inhibitor of mammalian cell cycle with potent differentiation-inducing activity in Friend leukemia cells

1 reference

12 December 2020

Loss of Expression ofGADD45γ, a Growth Inhibitory Gene, in Human Pituitary Adenomas: Implications for Tumorigenesis

1 reference

12 December 2020

Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA

1 reference

12 December 2020

Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island

1 reference

12 December 2020

Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2012.54

1 reference

26 August 2017

1 reference

PubMed ID

22525730